Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion

This study is currently recruiting participants.

Verified by Melbourne Health, October 2005

Sponsored by:	Melbourne Health
Information provided by:	Melbourne Health
ClinicalTrials.gov Identifier:	NCT00232219

Purpose

The purpose of this study is to investigate whether fish oil supplements may be beneficial in preventing the recurrence of atrial fibrillation after cardioversion.

Atrial fibrillation is a heart condition which can sometimes be successfully treated by a cardioversion.

Cardioversion involves resetting the heart back to normal with the use of electric current.

There is a tendency for the atrial fibrillation to recur , days weeks or even months after the cardioversion.

Fish oil supplements may be of benefit to patients with heart problems Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.

Condition	Intervention
Atrial Fibrillation	Drug: Fish oil

Genetics Home Reference related topics: Brugada syndrome familial atrial fibrillation short QT syndrome

Drug Information available for: Fish oil

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Randomized, Single Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion.

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Patients with persistent Atrial Fibrillation on Warfarin.

Exclusion Criteria:

paroxysmal atrial fibrillation with self terminating episodes.
left atrial size>6.0cm
myocardial infarction in the previous 6 months.
contraindications to amiodarone use .
cardiac surgery in the previous 3 months .
an acute reversible illness contributing to the development of af
a QTc interval > 480ms.
pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00232219

Contacts

Contact: Paul Sparks, MBBS,PhD, FRACP

0393427000 ext 27133

paul.sparks@mh.org.au

Locations

Australia, Victoria
Royal Melbourne hospital	Recruiting
Melbourne, Victoria, Australia, 3050
Contact: Paul Sparks, MBBS,PhD,FRACP 93427000 ext 27133 paul.sparks@mh.org.au
Contact: Fiona Sutherland 93427000 ext 27133 fiona.sutherland@mh.org.au

Sponsors and Collaborators

Melbourne Health

Investigators

Principal Investigator:

Paul Sparks, MBBS, PhD. FRACP

Melbourne Health

More Information

Study ID Numbers:	2003.188
Study First Received:	October 2, 2005
Last Updated:	October 2, 2005
ClinicalTrials.gov Identifier:	NCT00232219
Health Authority:	Australia: Department of Health and Ageing Therapeutic Goods Administration

Study placed in the following topic categories:

Heart Diseases
Atrial Fibrillation
Recurrence
Arrhythmias, Cardiac

Additional relevant MeSH terms:

Pathologic Processes
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009